FREMONT, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent ...
Zosano Pharma Corp. (ZSAN) saw its shares absolutely skyrocket on Monday after the firm gave an update on its late-stage trial for the treatment of migraines. Basically, the lead product candidate, ...
Zosano Pharma’s headaches are intensifying. With the FDA again knocking back its transdermal migraine patch, the biotech has suspended its M207 program and made more layoffs to preserve its dwindling ...
Zosano Pharma's migraines are getting worse: The biotech is looking at strategic alternatives and laying off 31% of its staff. The news follows last month's FDA decision to decline to review the ...
* Zosano pharma announces 3.8mg dose of m207, its novel transdermal therapeutic, meets both co-primary endpoints in the Zotrip pivotal efficacy trial in migraine ...
Federal Reserve Bank of Minneapolis President Neel Kashkari said Sunday that the longer the Iran war goes on, the greater the risks of higher inflation and economic damage, all of which limit how much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results